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Why carry out this study?
Despite the very widespread clinical use of
metformin, there is a lack of systematic
evidence to guide optimal selection of the
various formulations available.
What was learned from the study?
Updated data have now become available
to add to our systematic review and meta-
analysis.
Incorporation of these new data does not
substantively alter the conclusions of our
meta-analysis.
We showed that long-acting metformin
formulations have equal efficacy in
glycaemic control compared to
immediate-release metformin, with
additional benefits of reduced low-density
lipoprotein cholesterol concentrations
with extended-release metformin and
reduced gastrointestinal side effects with
delayed-release metformin.
This Editorial is based on a previous published article
(Tarry-Adkins JL et al. Efficacy and Side Effect Profile of
Different Formulations of Metformin: A Systematic
Review and Meta-Analysis. Diabetes Ther. 2021)
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EDITORIAL
Metformin is not a new drug, yet its use con-
tinues to expand for an ever-increasing range of
indications. Metformin is safe, relatively low
cost, easy to store, and simple to administer,
making it an attractive option for patients and
providers alike. Between 2007 and 2017, the
number of prescriptions issued for metformin in
the UK doubled to more than 20 million [1].
However when metformin scripts are issued,
there are surprisingly few robust sources of evi-
dence on which to make good clinical
decisions.
To tackle this evidence gap, we recently
performed a systematic review and meta-analy-
sis of all studies that compared different for-
mulations of metformin, i.e. immediate release
(IR), sustained release (also known as long-act-
ing or extended release; XR), or delayed release
(DR) [2]. Delayed release metformin is a new
formulation, with all global rights owned by
Anji Pharmaceuticals; it is currently available
only to participants in clinical studies. Studies
were included in our analysis if they involved a
head-to-head comparison of one or more dif-
ferent formulations. Overall, data were available
from 15 different studies that randomised a
total of 3765 participants.
Our results showed that in terms of gly-
caemic control, there were no significant dif-
ferences between the different formulations.
This alone is valuable evidence for the clinician
who seeks to optimise the management of dia-
betes. However, metformin’s use now extends
beyond diabetes care, making evaluation of
differences in other parameters increasingly
important. For example metformin XR was sig-
nificantly more effective than IR in lowering
low-density lipoprotein (LDL) cholesterol,
which may be an important benefit in patients
with significant obesity or other metabolic
disease.
A key influence on real-world efficacy of any
drug is tolerability. A drug with few unpleasant
side effects is much more likely to produce good
results outside of the highly regulated world of
clinical trials, because patients are more likely
to actually take it. An important element of our
study was therefore to assess whether there are
significant differences between metformin for-
mulations in terms of tolerability, in particular
the likelihood of experiencing gastrointestinal
side effects. Gastrointestinal effects are a major
barrier to tolerating metformin therapy, affect-
ing 20–30% of patients taking metformin.
Around 1 in 20 patients will experience effects
bothersome enough for them to stop taking
metformin altogether [3]. Longer-acting for-
mulations are often recommended to patients
who experience gastrointestinal side effects
with immediate release metformin, based on
the idea that there may be fewer unwanted
effects with these preparations. Our data sup-
port the idea that metformin DR is associated
with a significantly reduced likelihood of gas-
trointestinal side effects than metformin IR (OR
0.45, 95% CI 0.30–0.66, p\ 0.0001). When
metformin XR is compared to metformin IR,
there is also a reduction in the likelihood of
adverse gastrointestinal side effects, although
this does not reach our pre-specified threshold
for statistical significance.
Shortly after the online publication of our
study, further data regarding the likelihood of
gastrointestinal side effects with metformin XR
versus IR were made available to us by the data
holders of the 2003 study by Fujioka et al. [4].
This study was included in the original review,
but only a subset of the full data regarding fre-
quency of gastrointestinal side effects had been
published in the original manuscript. We had
previously requested the full data directly from
the authors but were not successful in contact-
ing them, perhaps unsurprisingly 17 years after
the original publication. Re-analysing our data
to include the previously unpublished full
results of the study by Fujioka et al. edges the
meta-analysis result further towards signifi-
cance, but it remains just below the pre-speci-
fied threshold and therefore there is no change
to the original conclusions of our meta-analysis.
It is entirely possible that if even more data were
available from other studies, there might be a
significantly reduced likelihood of gastroin-
testinal side effects with metformin XR com-
pared IR; however, this is not possible to
determine on the basis of available data.
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These data are an interesting addition to our
study and underscore the surprising paucity of
studies that have specifically addressed com-
parisons between metformin formulations.
Given that metformin is among the top five
most commonly prescribed drugs in the USA
[5], there is a clear research gap regarding both
the relative benefits of each available metformin
formulation and the health economic implica-
tions of prescribing each. Our meta-analysis
goes some way towards helping to clarify the
comparisons and we hope will thus be useful to
both prescribers and consumers of metformin
(Fig. 1).
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Fig. 1 The effect of metformin formulation upon
gastrointestinal side effects comparing met-XR versus
met-IR. This is an updated version of Fig. 5a within our
previous publication [2], now including additional data
from the study by Fujioka et al. [4] that has not previously
been published but was subsequently made available
outside of our pre-specified search strategy by kind
permission of Merck Healthcare KGaA. The addition of
this extra data does not alter the substantive conclusions of
the meta-analysis previously presented. There is a lower
likelihood of experiencing gastrointestinal side effects with
metformin XR than IR (OR 0.76, CI 0.58–1.00), but this
does not reach the pre-specified threshold for significance
(p = 0.05)
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